Pigmented Skin Lesion Clinical Trial
Official title:
Evaluation of a New Dermal Cryotherapy System for the Treatment of Benign Pigmented Lesions
NCT number | NCT02848742 |
Other study ID # | R2-16-001 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2016 |
Est. completion date | March 2020 |
Verified date | March 2021 |
Source | R2 Dermatology |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Study to evaluate the ability of the Dermal Cooling System to reduce pigmentation in benign pigmented lesions.
Status | Completed |
Enrollment | 377 |
Est. completion date | March 2020 |
Est. primary completion date | March 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Male or female subjects > 18 years of age. 2. Subject has one or more benign pigmented lesions (e.g., solar lentigines, melasma, freckles, café au lait, nevi, or hyperpigmentation), in an area suitable for treatment 3. Subject is willing to have up to 40 treatment sites and/or an area up to 8 square inches treated depending on the size and nature of the lesions identified. 4. Subject is willing to have digital photographs taken of the treatment area and agrees to use of photographs for presentation, educational, or marketing purposes. 5. Subject is willing to cover treated area or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treated areas for the duration of the study, including the follow-up period, if requested. 6. Subject has read and signed a written informed consent form. Exclusion Criteria: 1. Physician prescribed medical or surgical treatment, or use of over-the-counter products to alter skin color, in the area of intended treatment in the previous 6 months (e.g., hydroquinone, corticosteroids, laser surgery) 2. Artificial tanning in the area of intended treatment within 1 month (e.g., spray, lotion, tanning bed) or intention to use artificial tanning within the follow-up period 3. Scars or tattoos in the location of the treatment sites 4. History of vitiligo, eczema, or psoriasis in the area of treatment 5. History of melanoma 6. Known history of illness or adverse reaction to cold insult (e.g., cryoglobulinemia, cold urticaria, paroxysmal cold hemoglobinuria, Reynaud's disease. 7. History of abnormal wound healing or abnormal scarring 8. Inability or unwillingness to comply with the study requirements. 9. Current enrollment in a clinical study of any other unapproved investigational drug or device. 10. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject. |
Country | Name | City | State |
---|---|---|---|
Canada | Arbutus Laser Centre | Vancouver | British Columbia |
United States | Diablo Clinical Research | Walnut Creek | California |
Lead Sponsor | Collaborator |
---|---|
R2 Dermatology |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reduction of pigmentation in treated lesions | Changes in pigmentation graded using a 4-point standardized scale | 90 days | |
Secondary | Evaluation of device- or procedure-related adverse events | Side effects, discomfort assessments both during treatment and follow-up | 0 to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02613325 -
fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth
|
Phase 1 | |
Enrolling by invitation |
NCT04566302 -
Pilot Study of Imaging Human Skin With High-Speed Spectrally Encoded Confocal Microscopy
|
N/A | |
Completed |
NCT04202419 -
Nonablative Fractional Diode Laser for Treatment of Pigmented Lesions
|
N/A | |
Recruiting |
NCT06263413 -
Clinical Workflow Optimization Using Artificial Intelligence for Dermatological Conditions
|
||
Recruiting |
NCT03362138 -
Artificial Intelligence-assisted Evaluation of Pigmented Skin Lesions
|